Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 9:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 135 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Thrush Clear all
Completed Phase 3 Interventional

Study of Micafungin in Patients With Invasive Candidiasis or Candidemia

NCT00105144
View directory record Official record
Conditions
Candidiasis, Candidemia
Interventions
Micafungin, Caspofungin
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
62
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2014 · Synced Sep 12, 2026, 9:27 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis

NCT01926028
View directory record Official record
Conditions
Vulvovaginal Candidiasis
Interventions
NDV-3A, NDV-3, Placebo
Biological
Lead sponsor
NovaDigm Therapeutics, Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
20
States / cities
Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Sep 12, 2026, 9:27 PM EDT
Completed Phase 4 Interventional

Comparison of Two Treatments to Prevent Invasive Fungal Infections in Patients Who Have Received Liver Transplants

NCT00001107
View directory record Official record
Conditions
Candidiasis
Interventions
Fluconazole, AmBisome
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 26, 2010 · Synced Sep 12, 2026, 9:27 PM EDT
Completed Phase 2 Interventional

The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasis.

NCT00037219
View directory record Official record
Conditions
Candidiasis
Interventions
Anidulafungin, VER002
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
King of Prussia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 20, 2008 · Synced Sep 12, 2026, 9:27 PM EDT
Completed Not applicable Interventional

A Comparison of the Safety and Effectiveness of Fluconazole or Clotrimazole in the Treatment of Fungal Infections of the Mouth and Throat in Patients With AIDS

NCT00002282
View directory record Official record
Conditions
Candidiasis, Oral, HIV Infections
Interventions
Clotrimazole, Fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
17
States / cities
Los Angeles, California • Oakland, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 12, 2026, 9:27 PM EDT
Completed Not applicable Interventional

Clinical Study to Evaluate the Efficacy of an Anti-Fungal Supplement

NCT06146504
View directory record Official record
Conditions
Candida Systemic, Candida Albicans Infection, Candida Infection
Interventions
CanXida Remove (Formula RMV), Placebo
Dietary Supplement · Other
Lead sponsor
CanXida
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Sep 12, 2026, 9:27 PM EDT
Completed No phase listed Observational

Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization

NCT02888197
View directory record Official record
Conditions
Candidiasis, Vulvovaginal, Yeast Infection, Mycoses, Moniliasis, Vulvovaginal, Vaginitis, Monilial
Interventions
Not listed
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
23
States / cities
Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2018 · Synced Sep 12, 2026, 9:27 PM EDT
Terminated Phase 3 Interventional Results available

An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Deep Tissue Infection Due To Candida

NCT00805740
View directory record Official record
Conditions
Candidiasis, Fungemia
Interventions
Active anidulafungin, Active Caspofungin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
16 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
4
States / cities
Newark, Delaware • Wilmington, Delaware • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 31, 2013 · Synced Sep 12, 2026, 9:27 PM EDT
Recruiting Not applicable Interventional

Comparison of Uncomplicated Candidemia Therapy Duration in Children

NCT05763251
View directory record Official record
Conditions
Invasive Candidiasis
Interventions
therapy duration
Other
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
120 Days and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
21
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Orange, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 12, 2026, 9:27 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects

NCT00940017
View directory record Official record
Conditions
Aspergillosis, Candidemia
Interventions
anidulafungin and voriconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 8, 2010 · Synced Sep 12, 2026, 9:27 PM EDT
Completed Phase 1 Interventional

Rituximab for Anti-cytokine Autoantibody-Associated Diseases

NCT01842386
View directory record Official record
Conditions
Pulmonary Alveolar Proteinosis (PAP), Severe Mucocutaneous Candidiasis
Interventions
Rituximab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 12, 2026, 9:27 PM EDT
Completed No phase listed Observational

PEACE: Pediatric Antifungal Comparative Effectiveness

NCT01869829
View directory record Official record
Conditions
Pediatric Invasive Candidiasis
Interventions
Observational antifungal therapy
Drug
Lead sponsor
Duke University
Other
Eligibility
120 Days to 18 Years
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
27
States / cities
Little Rock, Arkansas • Orange, California • Palo Alto, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2022 · Synced Sep 12, 2026, 9:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Performance Study of the Cobas® BV/CV Test on Samples From Participants With and Without Symptoms of Bacterial Vaginosis and Candida Vaginitis

NCT06975436
View directory record Official record
Conditions
Bacterial Vaginosis, Candida Vaginitis
Interventions
cobas® BV/CV test, BD Max™ Vaginal Panel, Cepheid Xpert Xpress MVP, Hologic Aptima BV Assay
Diagnostic Test
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
14 Years and older · Female only
Enrollment
738 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
8
States / cities
Los Angeles, California • San Diego, California • Lakewood, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2025 · Synced Sep 12, 2026, 9:27 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effect of Exercise on Spread of the Miconozole Nitrate OVULE in the Vagina

NCT00194324
View directory record Official record
Conditions
Health, Vulvovaginal Candidiasis
Interventions
Miconazole nitrate, Magnetic resonance imaging, Moderate levels of exercise
Drug · Procedure · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 8, 2011 · Synced Sep 12, 2026, 9:27 PM EDT
Completed Phase 4 Interventional Results available

Randomized Study of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in the Intensive Care Unit (ICU)

NCT00520234
View directory record Official record
Conditions
Invasive Candidiasis
Interventions
Caspofungin, Normal Saline
Drug
Lead sponsor
Mycoses Study Group
Network
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 8, 2011 · Synced Sep 12, 2026, 9:27 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Vaginal Ecosystem and Network in the United States Study

NCT06472765
View directory record Official record
Conditions
Bacterial Vaginosis, Candidiasis, Urinary Tract Infections, Genitourinary Syndrome of Menopause, Lichen Sclerosus, Lichen Planus, Vulvodynia, Endometriosis, Ureaplasma Infections, Cancer, Desquamative Inflammatory Vaginitis
Interventions
Vaginal Swab Collection
Diagnostic Test
Lead sponsor
Vaginal Biome Science
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
3,250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
20
States / cities
Fullerton, California • Los Angeles, California • Pasadena, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2025 · Synced Sep 12, 2026, 9:27 PM EDT
Completed Phase 3 Interventional

Caspofungin to Prevent Candidiasis in Adults in Hospital Intensive Care Units

NCT00099775
View directory record Official record
Conditions
Candidiasis
Interventions
Caspofungin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 12, 2026, 9:27 PM EDT
Completed Phase 1 Interventional

Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the Drug

NCT00607763
View directory record Official record
Conditions
Invasive Candidiasis, Esophageal Candidiasis, Oropharyngeal Candidiasis, Candidemia
Interventions
Micafungin (Mycamine)
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
4 Months to 23 Months
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
6
States / cities
Los Angeles, California • Orange, California • Louisville, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2014 · Synced Sep 12, 2026, 9:27 PM EDT
Withdrawn No phase listed Observational

UARK 2009-99 A Non-interventional Observational Study of Infectious Complications in Cancer Patients

NCT01622595
View directory record Official record
Conditions
Aspergillosis, Candidemia, C. Difficile
Interventions
Not listed
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2015 · Synced Sep 12, 2026, 9:27 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Boric Acid Inserts for Treatment of Vulvovaginal Candidiasis

NCT07109869
View directory record Official record
Conditions
Vulvovaginal Candidiases, Vulvovaginal Candidiasis, Genital, Vulvovaginal Candidiasis (VVC)
Interventions
Boric acid, Placebo
Drug · Other
Lead sponsor
pH-D Feminine Health LLC
Industry
Eligibility
12 Years and older · Female only
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
26
States / cities
Mobile, Alabama • Little Rock, Arkansas • Huntington Park, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 12, 2026, 9:27 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment

NCT03059992
View directory record Official record
Conditions
Invasive Candidiasis, Mucocutaneous Candidiasis, Coccidioidomycosis, Histoplasmosis, Blastomycosis, Chronic Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis, Invasive Pulmonary Aspergillosis, Recurrent Vulvovaginal Candidiasis, Other Emerging Fungi
Interventions
Ibrexafungerp
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
20
States / cities
Birmingham, Alabama • Sacramento, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Sep 12, 2026, 9:27 PM EDT
Recruiting Not applicable Interventional

Clinical Study of a Vaginal Cooling Device for the Treatment of Vulvovaginal Candidiasis (VVC)

NCT06983041
View directory record Official record
Conditions
Vulvovaginal Candidiasis (VVC), Yeast Vaginitis
Interventions
vaginal cooling device
Device
Lead sponsor
Coologics, Inc
Industry
Eligibility
22 Years to 49 Years · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
10
States / cities
Jacksonville, Florida • Miami, Florida • Smyrna, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Sep 12, 2026, 9:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine

NCT01447407
View directory record Official record
Conditions
Staphylococcal Infections, Yeast Infections, Candidiasis
Interventions
NDV-3 vaccine with alum IM, NDV-3 vaccine without alum IM, Placebo with alum IM, NDV-3 vaccine without alum ID
Biological
Lead sponsor
NovaDigm Therapeutics, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
164 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Sep 12, 2026, 9:27 PM EDT
Not listed No phase listed Observational

Assessment of Assay for Rapid Identification of Bloodstream Infections From Whole Blood

NCT04147975
View directory record Official record
Conditions
Bacteremia, Candidemia
Interventions
RaPID/BSI Test
Diagnostic Test
Lead sponsor
HelixBind, Inc.
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Marlborough, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced Sep 12, 2026, 9:27 PM EDT